India to resume patented drug pricing efforts?
This article was originally published in Scrip
India appears set to renew its efforts towards finalizing a mechanism for price negotiations for patented drugs – a thorny issue and one that's been under deliberation for more than six years now.
You may also be interested in...
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.